SCHEMBL2045447

SCHEMBL2045447

CC(C)C(C)CCCC(C)(C)C

nearest known ligand 0.37

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19155761 0.82 RIPK1 (0.39) RIPK1
SCHEMBL10301504 0.81 ALDH1A1 (0.45)
SCHEMBL13241915 0.81 ALDH1A1 (0.45)
SCHEMBL9971880 0.81 ALDH1A1 (0.45)
SCHEMBL23874585 0.80
SCHEMBL6372324 0.79 RIPK1 (0.30) RIPK1
SCHEMBL17607530 0.79 MEN1 (0.31)
SCHEMBL27477460 0.78 RIPK1 (0.32) RIPK1
SCHEMBL10922168 0.77
SCHEMBL598576 0.77 MEN1 (0.45) RIPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200171214-A1 BIORESORBABLE SURFACE COATING FOR DELAYING DEGRADATION DREI LILIEN PVG GMBH & CO. KG (DE) 2020-06-04 US disclosed
EP-3648806-A1 BIORESORBABLE SURFACE COATING FOR DELAYING DEGRADATION Drei Lilien PVG GmbH & Co. KG (DE) 2020-05-13 EP disclosed
CN-106475059-B A kind of couple of C6Isomer has the ferrous metals organic framework material and the preparation method and application thereof of high adsorptive selectivity 华南理工大学 2018-12-11 CN disclosed
CN-104271242-A Catalyst for light naphtha aromatization SAUDI BASIC IND CORP 2015-01-07 CN disclosed
WO-2014071351-A1 METAL-ORGANIC FRAMEWORK FOR THE SEPARATION OF ALKANE ISOMERS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-05-08 WO disclosed
US-8198501-B2 Zeolite catalyst for hydroisomerization of light paraffins to produce high octane gasoline CHEVRON U.S.A. INC. (US) 2012-06-12 US disclosed
US-20110130610-A1 ZEOLITE CATALYST FOR HYDROISOMERIZATION OF LIGHT PARAFFINS TO PRODUCE HIGH OCTANE GASOLINE CHEVRON U.S.A. INC. 2011-06-02 US disclosed
EP-0014985-A1 Trialkylamine preparation by reductive alkylation of dialkylamines with ketones UNIROYAL, INC. (US) 1980-09-03 EP disclosed
US-4075259-A Saturated hydrocarbon isomerization utilizing a catalyst of platinum group metal, cobalt, tin and halogen on a carrier UOP INC. (US) 1978-02-21 US disclosed
US-4013738-A HYDROCARBON ISOMERIZATION PROCESS UOP INC. (US) 1977-03-22 US disclosed
US-3992476-A Paraffin isomerizaton with a catalytic composite of platinum or palladium metal, rhodium metal, tin oxide, halogen and alumina carrier UNIVERSAL OIL PRODUCTS COMPANY (US) 1976-11-16 US disclosed
US-3979476-A HYDROGEN FLUORIDE, ANTIMONY PENTAFLUORIDE ALKYLATION CATALYST CHEVRON RESEARCH COMPANY (US) 1976-09-07 US disclosed
US-3962360-A Alkylaromatic isomerization process UNIVERSAL OIL PRODUCTS COMPANY (US) 1976-06-08 US disclosed
US-3939102-A Hydrocarbon isomerization catalyst and process UNIVERSAL OIL PRODUCTS COMPANY (US) 1976-02-17 US disclosed
US-3933619-A HIGH OCTANE, LOW LEAD, HYDROCRACKING, ISOMERIZATION CHEVRON RESEARCH COMPANY (US) 1976-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110130610-A1 ZEOLITE CATALYST FOR HYDROISOMERIZATION OF LIGHT PARAFFINS TO PRODUCE HIGH OCTANE GASOLINE MAL2, AOC2, CTRB2 RIPK1 3772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.